156 related articles for article (PubMed ID: 6469507)
21. Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.
Zeller WJ; Berger MR; Matys R; Schuhmacher J
Invest New Drugs; 1984; 2(2):175-80. PubMed ID: 6469512
[TBL] [Abstract][Full Text] [Related]
22. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213).
Deconinck E; Tamayo E; Hervé P
Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586
[TBL] [Abstract][Full Text] [Related]
23. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase.
Bunting KD; Lindahl R; Townsend AJ
J Biol Chem; 1994 Sep; 269(37):23197-203. PubMed ID: 8083225
[TBL] [Abstract][Full Text] [Related]
24. Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions.
Saal JG; Hadam M; Frank F; Rautenstrauch H; Fritz P
Invest New Drugs; 1984; 2(2):231-5. PubMed ID: 6236165
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of human B lymphocyte differentiation by a stable metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
Gorski A; Korczak-Kowalska G
Invest New Drugs; 1984; 2(2):227-9. PubMed ID: 6236164
[TBL] [Abstract][Full Text] [Related]
26. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
27. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows.
Douay L; Gorin NC; Laporte JP; Lopez M; Najman A; Duhamel G
Invest New Drugs; 1984; 2(2):187-90. PubMed ID: 6381382
[TBL] [Abstract][Full Text] [Related]
28. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
29. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
[TBL] [Abstract][Full Text] [Related]
30. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
31. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated macrophages stimulate the proliferation of murine tumor cells surviving treatment with the oncolytic cyclophosphamide analogue Asta Z-7557: in vivo implications.
Evans R; Duffy T; Cullen RT
Int J Cancer; 1984 Dec; 34(6):883-90. PubMed ID: 6511127
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Invest New Drugs; 1984; 2(2):191-9. PubMed ID: 6469514
[TBL] [Abstract][Full Text] [Related]
34. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
35. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
36. A comparison of two cytotoxicity assays for the detection of metabolism-mediated toxicity in vitro: a study with cyclophosphamide.
Horner SA; Fry JR; Clothier RH; Balls M
Xenobiotica; 1985; 15(8-9):681-6. PubMed ID: 3878046
[TBL] [Abstract][Full Text] [Related]
37. Increased drug cytotoxicity at reduced pH counteracts cyclophosphamide resistance in cultured rat mammary carcinoma cells.
Jähde E; Glüsenkamp KH; Rajewsky MF
Int J Cancer; 1989 Dec; 44(6):1082-7. PubMed ID: 2606575
[TBL] [Abstract][Full Text] [Related]
38. Does acrolein contribute to the cytotoxicity of cyclophosphamide?
Wrabetz E; Peter G; Hohorst HJ
J Cancer Res Clin Oncol; 1980; 98(2):119-26. PubMed ID: 7217177
[TBL] [Abstract][Full Text] [Related]
39. Characterizing the ovotoxicity of cyclophosphamide metabolites on cultured mouse ovaries.
Desmeules P; Devine PJ
Toxicol Sci; 2006 Apr; 90(2):500-9. PubMed ID: 16381661
[TBL] [Abstract][Full Text] [Related]
40. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
